Dyne Therapeutics, Inc. (DYN)
18.00
+0.33
(+1.87%)
USD |
NASDAQ |
Jun 11, 14:07
Dyne Therapeutics Research and Development Expense (Quarterly) : 100.89M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 100.89M |
| December 31, 2025 | 95.43M |
| September 30, 2025 | 97.22M |
| June 30, 2025 | 99.24M |
| March 31, 2025 | 106.45M |
| December 31, 2024 | 81.80M |
| September 30, 2024 | 92.80M |
| June 30, 2024 | 62.26M |
| March 31, 2024 | 44.54M |
| December 31, 2023 | 58.84M |
| September 30, 2023 | 55.25M |
| June 30, 2023 | 59.13M |
| March 31, 2023 | 37.54M |
| Date | Value |
|---|---|
| December 31, 2022 | 33.19M |
| September 30, 2022 | 34.67M |
| June 30, 2022 | 46.66M |
| March 31, 2022 | 28.24M |
| December 31, 2021 | 42.30M |
| September 30, 2021 | 36.51M |
| June 30, 2021 | 23.87M |
| March 31, 2021 | 18.62M |
| December 31, 2020 | 22.10M |
| September 30, 2020 | 9.679M |
| December 31, 2019 | 4.259M |
| September 30, 2019 | 2.982M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Vor Biopharma, Inc. | 17.60M |
| BioCryst Pharmaceuticals, Inc. | 59.26M |
| Agenus, Inc. | 11.82M |
| Amgen, Inc. | 1.719B |
| Imunon, Inc. | 2.337M |